Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Raw Materials (2021 - 2024)

Historic Raw Materials for Universe Pharmaceuticals (UPC) over the last 5 years, with Q3 2025 value amounting to $2.5 billion.

  • Universe Pharmaceuticals' Raw Materials rose 15452.15% to $2.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year increase of 15452.15%. This contributed to the annual value of $2.5 billion for FY2025, which is 15452.15% up from last year.
  • Universe Pharmaceuticals' Raw Materials amounted to $2.5 billion in Q3 2025, which was up 15452.15% from $978.2 million recorded in Q3 2024.
  • Universe Pharmaceuticals' Raw Materials' 5-year high stood at $2.5 billion during Q3 2025, with a 5-year trough of $635395.0 in Q3 2023.
  • Over the past 5 years, Universe Pharmaceuticals' median Raw Materials value was $2.7 million (recorded in 2021), while the average stood at $694.5 million.
  • As far as peak fluctuations go, Universe Pharmaceuticals' Raw Materials plummeted by 6388.13% in 2022, and later surged by 15385195.11% in 2024.
  • Over the past 5 years, Universe Pharmaceuticals' Raw Materials (Quarter) stood at $2.7 million in 2021, then tumbled by 63.88% to $989043.0 in 2022, then tumbled by 35.76% to $635395.0 in 2023, then surged by 153851.95% to $978.2 million in 2024, then surged by 154.52% to $2.5 billion in 2025.
  • Its Raw Materials was $2.5 billion in Q3 2025, compared to $978.2 million in Q3 2024 and $635395.0 in Q3 2023.